Case report: Pembrolizumab as an alternative to atezolizumab following a severe infusion reaction

The emergence of immune-checkpoint inhibitors (ICIs) has revolutionized the field of oncology, providing promising results in various malignancies. However, ICIs can sometimes lead to severe injection reactions, requiring alternative treatment options. In this case report, we introduce a case of a s...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Seung Hyuk Lee, Hyeon Jong Kim, Hyun Jin Bang, Su Ji Park, Ji Eun Yu, Seung Woo Jeong, Woo Kyun Bae
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	Frontiers Media S.A. 2024-03-01
Edice:	Frontiers in Oncology
Témata:	immune-checkpoint inhibitors (ICIs) atezolizumab pembrolizumab infusion reaction hypersensitivity immune-related adverse drug reactions (ADRs)
On-line přístup:	https://www.frontiersin.org/articles/10.3389/fonc.2024.1273043/full
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!